Indications for: ADBRY
Moderate to severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. May be used with or without topical corticosteroids.
Give by SC inj into the thigh or abdomen (except for 2 inches around the navel); upper arm may be used if caregiver administers inj. Rotate inj sites. Initially 600mg (four 150mg inj), followed by 300mg (two 150mg inj) every other week. After 16 weeks, may consider 300mg every 4 weeks for patients weighing <100kg who achieve clear or almost clear skin. Concomitant topical calcineurin inhibitors: reserve for problem areas only (eg, face, neck, intertriginous, genital areas).
Discontinue immediately if serious hypersensitivity reactions occur. New onset or worsening eye symptoms. Helminth infections: treat pre-existing infections prior to initiation; discontinue Adbry if become infected during therapy until infection resolves. Complete all vaccinations according to current guidelines prior to initiation. Pregnancy. Nursing mothers.
Interleukin-13 (IL-13) antagonist.
Avoid concomitant live vaccines.
Upper respiratory tract infections, conjunctivitis, inj site reactions, eosinophilia; anaphylaxis, angioedema, keratitis.
Generic Drug Availability:
Single-dose prefilled syringe (w. needle guard)—2, 4